GreenLight Biosciences, Inc.
200 Boston Avenue
About GreenLight Biosciences, Inc.
GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform to deliver higher-quality RNA at a lower cost and more quickly than was ever before possible.
GreenLight develops RNA products and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, plant protection and support the health of bees and other pollinators. The GreenLight team values diversity, inclusion, and equality and promises to use collaboration to remain scientifically imaginative and passionately focused on making a difference in the world.
GreenLight is currently innovating in both the agriculture and life sciences industries. We aim to bring safe, effective solutions to market that are driven by rigorous scientific innovation. With your skills, you can help us get there.
CEO Andrey Zarur on the personal reason he founded GreenLight Biosciences
52 articles about GreenLight Biosciences, Inc.
GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today released its inaugural Sustainability Report.
GreenLight Biosciences confirmed that it has received a non-binding indication of interest from Fall Line Endurance Fund, L.P. to acquire all of the outstanding capital stock of the Company for $0.60 per share in cash.
GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today reported operational highlights and financial results for the fourth quarter and full year ended December 31, 2022.
GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Human Health R&D Day
GreenLight Biosciences will today outline its pipeline strategy and R&D progress for mRNA-based solutions during its Human Health R&D Day being held today, March 9, 2023 at 10:30 a.m. ET in Lexington, MA.
GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Plant Health R&D Day
GreenLight Biosciences will outline its pipeline strategy and R&D progress for dsRNA based crop protection and plant delivery innovations focused on addressing food security with innovative and sustainable solutions during its Plant Health R&D Day being held today, March 7th, 2023 at 10:30 a.m. ET in Research Triangle, North Carolina.
GreenLight Biosciences, a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, announced it will host a two-part R&D Day Series for analysts and investors.
GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate
GreenLight Biosciences today announced that it has received regulatory approval from the Rwanda Food and Drugs Authority (Rwanda FDA) to start a Phase I/II clinical trial of its vaccine candidate against Covid-19, as a booster to previously vaccinated individuals. Preparations for the trial are underway.
GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines
GreenLight Biosciences Holdings, PBC (Nasdaq:GRNA), and EpiVax Therapeutics Inc, today announced that they have signed an exclusive collaboration agreement to jointly develop and commercialize personalized mRNA-based vaccine candidates for cancers.
GreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
GreenLight Biosciences Holdings, PBC today reported operational highlights and financial results for the third quarter ended September 30, 2022.
GreenLight Biosciences announced that Dr. Andrey Zarur, CEO, and Susan Keefe, CFO will participate in two upcoming investor conferences in November.
As part of a realignment, GreenLight Biosciences is cutting staff by about 25%, the company announced Wednesday.
GreenLight Biosciences announced a realignment to focus on key near-term value drivers and extend its cash runway.
GreenLight Biosciences and Queensland University of Technology partner to tackle destructive fall armyworm using RNA
GreenLight Biosciences and Queensland University of Technology (QUT) partner to create a solution for fall armyworm.
GreenLight Biosciences Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
GreenLight Biosciences today reported operational highlights and financial results for the second quarter ended June 30, 2022.
CRISPR Therapeutics, Clovis Oncology and VistaGen all released Q2 results this week, while GreenLight Biosciences has some extra cash to work with.
GreenLight Biosciences today announced a private placement of approximately $109 million.
GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine
GreenLight Biosciences and Samsung Biologics announced the successful completion of the first commercial-scale engineering run for the companies’ mRNA production partnership.
GreenLight Biosciences has announced a collaboration with the National Institutes of Health to develop COVID-19 vaccines that are more broadly protective against new variants and with longer-lasting effects.
An RNA-based solution by GreenLight Biosciences designed to protect honeybees from the Varroa destructor mite was named a finalist by Fast Company for its 2022 World Changing Ideas Awards.
GreenLight Biosciences, PBC, a biotechnology company focused on RNA research, product design, development, and manufacturing for human, animal, and plant health, is proud to welcome Barney Graham, MD, PhD., to its Human Health Scientific Advisory Board.